Grace Therapeutics Inc (GRCE) Q4 2026 Earnings Report

Grace Therapeutics (GRCE) reported no product revenue for Q4 2026 and continued to operate as a clinical‑stage biotechnology company. The quarter shows a material operating loss (operating income: -$5.619 million) driven by R&D and other operating costs, partially offset by significant non‑operating income (total other income/expenses net: +$2.742 million) that reduced the reported net loss to -$427,775 (EPS: -$0.06). R&D expense in the quarter was $420,000 and G&A was $308,589. EBITDA was negative at -$5.617 million. The result represents an improvement in net income year‑over‑year, but operating performance remains loss-making and dependent on non‑operating items in this period. No revenue or formal forward guidance was provided in the filing. Investors should treat GRCE as a high‑risk, binary clinical‑stage equity where progress on key clinical milestones and access to capital will be primary value drivers.